A Randomized, Double-Blind Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin type B in Sialorrhea in ALS

Jackson, Carlayne E., MD
University of Texas Health Science Center at San Antonio

Rosenfeld, Jeffrey, Ph.D., M.D.
Carolinas Neuromuscular / ALS Center Barohn, Richard, M.D. University of Kansas Medical Center

Hypothesis:
This pilot study is designed to obtain data regarding the safety and efficacy of Botulinum toxin type B (Myobloc) in decreasing drooling in patients with ALS.  Information obtained from this trial will also provide new information on the effect of Myobloc treatment on quality of life and caregiver burden.

Aim:
To determine patient perception of benefit of Botulinum toxin type B (Myobloc) treatment for sialorrhea in ALS patients.

Status:
To date 10 patients have been enrolled in this study.  The patients have tolerated the injections well and no adverse events have been reported. The study is continuing.